Category: 3. Business

  • Independent Non-Executive Chairman of AMA Group Picks Up 2.6% More Stock

    Independent Non-Executive Chairman of AMA Group Picks Up 2.6% More Stock

    Investors who take an interest in AMA Group Limited (ASX:AMA) should definitely note that the Independent Non-Executive Chairman, Brian Austin, recently paid AU$0.99 per share to buy AU$197k worth of the stock. Although the purchase only increased their holding by 2.6%, it is still a solid purchase in our view.

    We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

    In fact, the recent purchase by Independent Non-Executive Chairman Brian Austin was not their only acquisition of AMA Group shares this year. Earlier in the year, they paid AU$1.00 per share in a AU$499k purchase. That means that an insider was happy to buy shares at above the current price of AU$0.93. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

    In the last twelve months AMA Group insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

    View our latest analysis for AMA Group

    ASX:AMA Insider Trading Volume November 8th 2025

    There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

    Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that AMA Group insiders own 8.9% of the company, worth about AU$40m. While this is a strong but not outstanding level of insider ownership, it’s enough to indicate some alignment between management and smaller shareholders.

    It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. However, we note that the company didn’t make a profit over the last twelve months, which makes us cautious. Insiders likely see value in AMA Group shares, given these transactions (along with notable insider ownership of the company). Therefore, you should definitely take a look at this FREE report showing analyst forecasts for AMA Group.

    If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

    For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

  • Assessing Donaldson (DCI) Valuation After Steady Share Price Gains and Strong Long-Term Performance

    Assessing Donaldson (DCI) Valuation After Steady Share Price Gains and Strong Long-Term Performance

    Donaldson Company (DCI) shares have shown steady performance this month, rising as investors continue to consider the company’s latest financial results and broader industry trends. With steady revenue and net income growth, DCI remains a point of conversation.

    See our latest analysis for Donaldson Company.

    Donaldson Company’s share price continues to build positive momentum, climbing more than 4% over the past month and racking up an impressive year-to-date share price return of 29%. While recent gains have attracted attention, the company’s long-term results speak for themselves, with a total shareholder return of 53% over three years and more than 75% over five years. This reflects sustained performance and market confidence.

    If you’re interested in what else is showing strong momentum, this is a great time to broaden your view and discover fast growing stocks with high insider ownership

    But after such strong recent returns, investors may be wondering if Donaldson’s share price is undervalued and offering further upside, or if the market is now fully factoring in the company’s future growth prospects.

    Donaldson Company’s share price closed at $86.86, comfortably above the $80.00 fair value estimated in the most popular narrative. This invites a closer look at what analysts believe is powering the company’s valuation, and why the market may have already priced in much of the anticipated upside.

    Global expansion of environmental regulations and emissions standards is increasing demand for advanced filtration across industrial and transportation sectors. This is positioning Donaldson to achieve record sales in both Industrial Solutions and Mobile Solutions, with a direct positive impact on revenue and earnings growth in FY26 and beyond.

    Read the complete narrative.

    Curious about the projections driving this premium? There is a bold profit margin shift and potential record earnings on the table. Find out the financial levers behind this outlook and the one number that could turn the whole story upside down.

    Result: Fair Value of $80.00 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent delays in bioprocessing and a heavy reliance on aftermarket sales could slow revenue growth or disrupt earnings predictability in the future.

    Find out about the key risks to this Donaldson Company narrative.

    If you see the story differently or want to dig into the details yourself, you can build your own perspective in just a few minutes. Do it your way

    A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding Donaldson Company.

    Get ahead of the market and unlock fresh investment ideas tailored to your strategy by exploring these standout stock selections. Don’t let your next winner slip by.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include DCI.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Valuation Perspectives After Strong Earnings, Raised Guidance, and Strategic Microsoft Partnership

    Valuation Perspectives After Strong Earnings, Raised Guidance, and Strategic Microsoft Partnership

    AvePoint (AVPT) just delivered a notable update for investors, announcing strong quarterly earnings with significant increases in revenue and profit compared to the previous year. The company also raised its full-year guidance, signaling renewed momentum.

    See our latest analysis for AvePoint.

    Despite posting standout earnings and forming a strategic partnership with a key Microsoft channel group, AvePoint’s share price has pulled back recently, dropping over 20% in the past month and sitting down roughly 27% year-to-date. However, its three-year total shareholder return is an impressive 159%, showing long-term holders have been well rewarded even as short-term momentum has faded.

    If AvePoint’s run of news has you thinking bigger, this could be an ideal time to broaden your investing lens and explore fast growing stocks with high insider ownership

    With AvePoint delivering robust growth, boosting guidance, and gaining fresh Wall Street support, investors are left to consider if the recent selloff is an overreaction that offers value or if all future gains are already reflected in the price.

    With AvePoint closing at $12.08 and the most-followed narrative putting fair value over 40% higher, expectations are diverging from the current market pricing. The narrative’s thesis leans heavily on the company’s platform expansion and its evolving industry role.

    The accelerating enterprise adoption of AI tools like Microsoft Copilot, alongside increasing security and data governance challenges, is positioning AvePoint’s data management and governance solutions as mission-critical, which is driving robust customer expansions and higher spending per customer. This acts as a catalyst for sustained revenue growth and stronger net retention rates.

    Read the complete narrative.

    Curious about the bold numerical leaps this narrative is built on? The valuation hinges on a future profit metric more commonly reserved for elite software players and is underpinned by a growth outlook that defies conventional sector averages. Ready to see what is powering this valuation gap? Dive deep to discover which financial projections carry the most weight in the narrative’s fair value.

    Result: Fair Value of $21.02 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, rising competition from cloud giants and AvePoint’s continued reliance on Microsoft’s ecosystem could dampen the outlook and limit future gains.

    Find out about the key risks to this AvePoint narrative.

    Looking from a market multiples angle, AvePoint’s price-to-sales ratio stands at 6.6x, which is notably higher than both the US Software industry average of 4.9x and the peer group average of 4.8x. This premium could signal higher expectations baked into the price, increasing the risk if growth falls short. The fair ratio, calculated at 5.8x, sits below the current mark. Could the market eventually reset closer to this benchmark, or will AvePoint’s momentum justify its elevated valuation?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:AVPT PS Ratio as at Nov 2025

    If you see things differently or want to run the numbers your own way, it only takes a few minutes to craft your own perspective, so why not Do it your way

    A great starting point for your AvePoint research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

    Smart investors know that real opportunity comes from expanding their watchlist. Unlock fresh insights and jump ahead by scoping out these powerful market themes now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include AVPT.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • RS Group plc (EENEF) Q2 2026 Earnings Call Transcript – Seeking Alpha

    1. RS Group plc (EENEF) Q2 2026 Earnings Call Transcript  Seeking Alpha
    2. RS remains on track despite soft markets  Investors’ Chronicle
    3. RS Group stock rating upgraded to Buy by Deutsche Bank on improved trends  Investing.com
    4. Deutsche Bank backs RS Group for recovery as sales and cash flow steady  Proactive Investors
    5. RS Group posts profit rise amid improved second-quarter sales trend  MarketScreener

    Continue Reading

  • Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

    Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

    Pending the results of the ongoing phase 3 SORENTO trial (NCT05050942), increasing the dose or shortening the treatment interval of somatostatin analogs may be a viable route to take for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in need of symptom and/or disease control, according to Jennifer Chan, MD, MPH.

    “We’re awaiting the results of the SORENTO trial, which is looking at a novel highly bioavailable formulation of octreotide, a self-administered formulation of octreotide, that will be addressing this issue of whether dose and bioavailability matter,” Chan said in an interview with OncLive® during the 2025 NANETS Multidisciplinary NET Medical Symposium.1,2

    “In that trial, patients were randomly assigned to receive CAM2029, this novel version of octreotide, or standard dose octreotide or lanreotide. [Results] from that trial [will inform] whether that formulation, which is more bioavailable [than octreotide or lanreotide], may have superior efficacy to standard dosing,” Chan added.

    In the interview, Chan, the clinical director of the Gastrointestinal Cancer Center, director of the Program in Carcinoid and Neuroendocrine Tumors, and an institute physician at Dana-Farber Cancer Institute, and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts, discussed the relationship between dose escalation and symptom control, the evidence that supports potential disease control benefits, and how results from the SORENTO trial could redefine current standards.

    Chan’s Topline Takeaways on Optimizing Somatostatin Analog Use in GEP-NETs

    • Increasing octreotide LAR to 40 mg or 60 mg or shortening lanreotide intervals can improve control of carcinoid syndrome symptoms like flushing and diarrhea.
    • Observational data from trials such as NETTER-1, NETTER-2, and CLARINET FORTE suggest higher doses or shorter dosing intervals may prolong disease stability.
    • The ongoing phase 3 SORENTO trial is testing a novel, self-administered, highly bioavailable octreotide that could reshape somatostatin analog dosing paradigms.

    OncLive: What new data support individualized dose escalation or interval shortening of somatostatin analogs in patients with uncontrolled symptoms or disease progression?

    Chan: We often will adjust the dose of somatostatin analogs either by increasing the dose of octreotide long-acting repeatable [LAR] from the standard dose of 30 mg, [to] 40 mg or 60 mg, if there are uncontrolled symptoms of carcinoid syndrome. Sometimes that dose escalation can help minimize the symptoms of flushing and diarrhea, for instance. We also have information from the control arms from, for instance, the NETTER-1 [NCT01578239] and the NETTER-2 [NCT03972488] trials, that suggest that even in patients who might have higher grade disease, for instance in the NETTER-2 trial, or patients who may have progressed after standard dose somatostatin analog, as was the case in the NETTER-1 trial, that there may be some period of disease control by increasing the dose from 30 mg to 60 mg of octreotide LAR.

    There was also the phase 2 CLARINET FORTE trial [NCT02651987] that showed for lanreotide, another somatostatin analog, that if you shorten the interval from the usual 120 mg every 4 weeks to 120 mg every 2 weeks, patients who had progressed on standard dose [therapy] might achieve some progression-free survival benefit with the dose escalation.

    What factors should guide the decision to intensify or switch somatostatin analog therapy, and how do these strategies align with evolving guideline recommendations?

    In clinical practice, we probably most commonly will escalate the dose. For octreotide, [we’ll either] increase from the standard [dose of] 30 mg to 40 mg or 60 mg to help with symptom control. Uncontrolled carcinoid syndrome is probably the most common reason we adjust the dose.

    The same thing could be said for lanreotide. The 120 mg every 4 weeks, we may give more frequently, either every 3 weeks or every 2 weeks, mainly for symptom control. That is consistent with what’s in the National Comprehensive Cancer Network guidelines, for instance, for dose adjustment for symptom control. There’s less controlled data about dose escalation for disease control, but there are some observational results from the control arms of other studies that suggest [we] may achieve some disease control, but we’re awaiting the results of trials to help us understand that better.

    References

    1. Dose optimisation of SSAs: the evolving story in GEP-NET management; supported by Camurus. Presented at: 2025 NANETS Multidisciplinary NET Medical Symposium; October 23-25, 2025; Austin, Texas.
    2. A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET (SORENTO). Clinicaltrials.gov. Updated November 6, 2025. Accessed November 7, 2025. https://clinicaltrials.gov/study/NCT05050942

    Continue Reading

  • Evaluating Valuation After Recent Share Price Pullback

    Evaluating Valuation After Recent Share Price Pullback

    ACI Worldwide (ACIW) shares moved lower after the company’s latest trading session, closing down 3% to $48.96. While the decline caught some attention, it follows an otherwise resilient performance over the past month.

    See our latest analysis for ACI Worldwide.

    Zooming out, ACI Worldwide’s 1-year total shareholder return is down 15.6%, even as the stock still holds a notable 135.6% total return over three years. While momentum has been uneven, longer-term holders have seen substantial gains compared to short-term setbacks. This indicates that sentiment can change quickly based on recent events or evolving risks.

    If you’re watching for the next market mover or sector trend, this is a great moment to broaden your view and discover fast growing stocks with high insider ownership

    With mixed signals from recent returns and a sizable discount to some analyst price targets, the question is whether ACI Worldwide is an overlooked bargain or if the market has already priced in its growth potential.

    ACI Worldwide’s most followed narrative places its fair value sharply above the current stock price. This makes the recent dip appear even more striking. The gap suggests upbeat future expectations and invites a closer look at what is fueling such optimism.

    The official launch and positive customer reception of Connetic, ACI’s next-generation cloud-native payments hub with AI-powered decisioning and real-time capabilities, positions the company to capitalize on increasing demand for scalable, secure digital payment processing and real-time payments globally. This supports accelerating recurring revenue growth and higher margins. ACI’s established ability to facilitate alternative payment types, including stablecoins and digital currencies, enables it to capture new market opportunities as the complexity and adoption of digital payment methods rise. This development may translate into increased transaction volumes and elevated per-transaction economics, potentially driving revenue uplift.

    Read the complete narrative.

    Want to discover the secret behind this premium price tag? The narrative depends on a future where record bookings, cutting-edge innovation, and shifting profit margins shape a bold valuation. Could these projections become game-changers or merely raise more questions? Explore the full story to see the metrics that matter most.

    Result: Fair Value of $64.6 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, intensifying competition from fintechs and ongoing heavy investment demands could limit ACI Worldwide’s ability to deliver on its ambitious earnings projections.

    Find out about the key risks to this ACI Worldwide narrative.

    If the current story doesn’t fit your outlook or you prefer digging into the numbers on your own, crafting your personal analysis takes just minutes, so why not Do it your way

    A great starting point for your ACI Worldwide research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

    Why stop at one idea? There’s a world of potential winners waiting for you, and the right tool makes all the difference. Use Simply Wall Street’s screener to spot tomorrow’s top performers before everyone else. Maximize your search and gain an edge. Don’t let standout investments pass you by.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ACIW.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Assessing Valuation After Record Q3 Output, Hess Acquisition, and Shareholder Return Strength

    Assessing Valuation After Record Q3 Output, Hess Acquisition, and Shareholder Return Strength

    Chevron (CVX) caught investors’ attention this week after the company topped third-quarter earnings forecasts and set a new production record. This was supported by the freshly integrated Hess assets and output growth in key fields.

    Even as oil prices wavered and analysts weighed short-term concerns, Chevron maintained steady shareholder returns through both dividends and share buybacks. These latest results have become a talking point on Wall Street.

    See our latest analysis for Chevron.

    Shares of Chevron have climbed 5.7% year-to-date, and while the 1-year total shareholder return stands at a modest 3.3%, the company is coming off a highly active quarter. The quarter capped record output and the completion of its transformative Hess acquisition. Recent board changes and robust buybacks further highlight Chevron’s evolving strategy, keeping sentiment constructive even as near-term earnings forecasts soften. Overall, momentum is steady, and big-picture performance remains healthy for long-term holders.

    If you’re keen to uncover more opportunities in energy, now could be a smart time to check out fast growing stocks with high insider ownership.

    With Chevron trading at a double-digit discount to analyst price targets, but facing declining earnings estimates, investors are left to consider whether there is value still on the table or if the market fully reflects its future growth prospects.

    Chevron’s most widely followed narrative places its fair value at $172.04, which is noticeably above the last close of $155.02. With this gap in focus, Chevron’s current price may not reflect the narrative’s full expectations for long-term growth, earnings, and operational leverage.

    Strength in low-cost production and strategic acquisitions positions Chevron for revenue growth, operational leverage, and resilience to commodity price cycles. Investment in efficiency, renewables, and cost reductions supports industry-leading margins, shareholder returns, and diversified growth amid regulatory shifts.

    Read the complete narrative.

    Want to know the growth blueprint behind this high valuation? The key element of this narrative is record-breaking earnings and a future profit multiple usually associated with tech leaders. Interested in which bold financial projections support that price target? Dive deeper to see the surprising numbers that drive this fair value calculation.

    Result: Fair Value of $172.04 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent reliance on hydrocarbons and slow progress in renewables could impact Chevron’s revenue growth and long-term earnings stability.

    Find out about the key risks to this Chevron narrative.

    When we compare Chevron’s share price using standard industry ratios, the numbers present a very different story. The company trades at a price-to-earnings ratio of 24.4x, which is much higher than both the US Oil and Gas industry average (13.5x) and the peer average (20.7x). This suggests that, even accounting for Chevron’s scale and strengths, investors are paying a substantial premium. This premium exceeds what our fair ratio of 23.5x would indicate. Is this premium justified, or could it be leaving investors with less upside?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:CVX PE Ratio as at Nov 2025

    If you see Chevron’s value differently or want to examine the numbers from another angle, you can build your own narrative in minutes, Do it your way.

    A great starting point for your Chevron research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

    Smart investors look beyond the headlines. Don’t let great opportunities pass you by; take action now and broaden your research with these proven stock screeners:

    • Unlock potential income by targeting companies offering strong payouts through these 16 dividend stocks with yields > 3%, which reveal stocks yielding above 3% and rewarding shareholders.

    • Advance your portfolio into tomorrow by selecting innovators from these 24 AI penny stocks that are driving breakthroughs in artificial intelligence and redefining industry standards.

    • Build value by starting with these 870 undervalued stocks based on cash flows, highlighting stocks currently trading below their calculated cash flow and positioning yourself for long-term returns.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include CVX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • JFrog (FROG) Is Up 26.4% After Surpassing Q3 Estimates and Lifting Full-Year Cloud Outlook

    JFrog (FROG) Is Up 26.4% After Surpassing Q3 Estimates and Lifting Full-Year Cloud Outlook

    • JFrog has reported third-quarter results that exceeded analyst expectations, highlighted by a record US$136.91 million in revenue and a 50% year-over-year increase in cloud revenue, with the company also raising its outlook for the fourth quarter and full year 2025.

    • Cloud revenue now accounts for 46% of total sales, indicating a marked shift toward cloud-based services and reinforcing JFrog’s role in software supply chain management as enterprises increase adoption of AI-driven solutions.

    • We’ll explore how JFrog’s accelerating cloud revenue growth impacts its investment narrative and future expectations for sustainable earnings expansion.

    Uncover the next big thing with financially sound penny stocks that balance risk and reward.

    Owning JFrog means believing that trusted software supply chain management, especially with a focus on cloud and AI model delivery, will see ongoing enterprise adoption at scale. The recent Q3 results and raised 2025 guidance are clear positives for near-term sentiment, particularly given the 50% surge in cloud revenue; however, the most important catalyst, continued acceleration of cloud and security product adoption, remains vulnerable to competition and evolving enterprise IT buying patterns, while ongoing operating losses highlight the biggest risk right now. The strong quarter strengthens the company’s growth narrative, but does not remove the risk of lumpy enterprise deal flow and longer sales cycles tied to cloud migration trends. One announcement standing out this quarter is JFrog’s launch of new AI agent-based features and JFrog Fly, which enhance automation and developer workflow within its core platform. These innovations tie directly to the catalyst of deeper enterprise integration for trusted AI and hybrid deployments, supporting the potential for sustained growth but not fully offsetting risks associated with margin pressure as larger rivals embrace similar strategies. Yet even amid this progress, investors should pay close attention to how heightened competition could pressure JFrog’s pricing power and margins…

    Read the full narrative on JFrog (it’s free!)

    JFrog’s narrative projects $736.3 million revenue and $96.4 million earnings by 2028. This requires 15.8% yearly revenue growth and a $182.7 million increase in earnings from -$86.3 million.

    Uncover how JFrog’s forecasts yield a $56.44 fair value, a 6% downside to its current price.

    FROG Community Fair Values as at Nov 2025

    Four recent fair value estimates from the Simply Wall St Community put JFrog’s share price between US$35 and US$141. Some see opportunities as AI-driven DevOps gains traction, but others caution that risks like pricing pressure could limit upside. Consider exploring a range of these views.

    Explore 4 other fair value estimates on JFrog – why the stock might be worth over 2x more than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    • A great starting point for your JFrog research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

    • Our free JFrog research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate JFrog’s overall financial health at a glance.

    Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include FROG.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Rheinmetall AG (RHM:CA) Q3 2025 Earnings Call Transcript – Seeking Alpha

    1. Rheinmetall AG (RHM:CA) Q3 2025 Earnings Call Transcript  Seeking Alpha
    2. Financial report for Q3 2025 – Rheinmetall shows steady growth  Rheinmetall
    3. Rheinmetall (RNMBF) Stays on Track Amid Order Delays  GuruFocus
    4. Rheinmetall on track for FY25 targets as backlog rises 22.9%  Army Technology
    5. Rheinmetall looks to international partners as its sales grow  Shephard Media

    Continue Reading

  • A crisis at chipmaker Nexperia sent automakers scrambling. Here’s what to know

    A crisis at chipmaker Nexperia sent automakers scrambling. Here’s what to know

    A battle for control of a little-known chipmaker has threatened global auto production by choking off the semiconductor supply chain, though there are signs the crisis is inching toward a resolution.

    The power struggle over Nexperia, a Chinese-owned Dutch semiconductor maker, highlights how technology supply chain vulnerabilities are squeezing auto makers, most notably forcing Honda to halt production at a Mexican factory making its popular HR-V crossover for North American markets. It also exposes how Europe is caught in the middle of the wider geopolitical showdown between Washington and Beijing.

    Here’s a look at the dispute:

    The turmoil erupted into public view in mid-October, when the Dutch government announced it had invoked a rarely used World War II-era law to take effective control of Nexperia weeks earlier.

    The Dutch ministry of economic affairs said it took action because of national security concerns. Officials said they intervened because of “serious governance shortcomings” at Nexperia, asserting control to prevent the loss of crucial tech know-how that could threaten Europe’s economic security.

    Nexperia’s Chinese owner Wingtech Technology, a partially state-owned company, is at the heart of the dispute. Amid the boardroom battle, a Dutch court granted the ministry’s request to oust Nexperia’s Chinese CEO Zhang Xuezheng. American officials told the Dutch government he would have to be replaced to avoid trade restrictions, according to a court filing.

    Nexperia makes simple semiconductors such as switches and logic chips. The auto industry — one of Nexperia’s biggest markets — uses its chips for numerous functions, such as adaptive LED headlight controllers, electric vehicle battery management systems and anti-lock brakes.

    Headquartered in the Dutch city of Nijmegen, Nexperia was spun off from Philips Semiconductors two decades ago. It was eventually purchased by China’s Wingtech Technology in 2018 for $3.6 billion.

    Nexperia has wafer fabrication plants in Britain and Germany. It operates an assembly and testing center in China’s southern manufacturing heartland of Guangdong — which accounts for around 70% of its end-product capacity — and similar centers in the Philippines and Malaysia.

    The dispute is part of the broader struggle between the U.S. and China over tech supremacy, which has left Europe caught in the middle.

    It stems from Washington’s decision late last year to place Wingtech on its “entity list,” which subjects companies to export controls because of national security risks. In late September, the U.S. expanded that list to Wingtech’s subsidiaries, including Nexperia, pressuring allies to follow suit.

    After the Dutch government asserted control of Nexperia, Beijing responded soon after, blocking the export of Nexperia chips from its assembly plant in the Chinese city of Dongguan. It blamed the Netherlands for “turmoil and chaos” in the chip supply chain.

    There were signs of hope following last month’s high-profile meeting between U.S. President Donald Trump and Chinese leader Xi Jinping, when the White House said Beijing would ease the export ban as part of a U.S.-China trade truce.

    Despite Beijing also confirming exports would be allowed to resume, Nexperia’s Chinese unit said headquarters suspended shipments of wafers used to make chips to its Chinese factory, potentially crimping its ability to deliver finished products.

    Nexperia’s head office hit back in a statement Wednesday, saying the Chinese unit refused to pay for the wafers and accused it of “ignoring the lawful instructions” from its global management team. The company said it can’t guarantee the quality of any chips delivered from its China plant since Oct. 13.

    Modern automobiles rely on so-called discrete chips made by companies like Nexperia, which, unlike more advanced microprocessors, perform a single function. Leaders at big carmakers spelled out their worries in the latest round of earnings calls, saying that finding a replacement for Nexperia at scale in the short term will be difficult.

    “While Nexperia makes up only about 5% of the automotive silicon discrete market in term of revenue, its share is much higher in terms of discrete chip volume,” S&P Global Mobility analysts wrote in a recent note.

    Nexperia’s parts are widely used across vehicle systems — often dozens to hundreds per vehicle — and carmakers in North America, Japan and South Korea are at risk, they added.

    “It’s an industrywide issue. A quick breakthrough is really necessary to avoid fourth quarter production losses for the entire industry,” Ford CEO Jim Farley said.

    General Motors CEO Mary Barra warned that production could be hit. The company has “teams working around the clock with our supply chain partners to minimize possible disruptions,” she said.

    Nissan CEO Ivan Espinosa told CNBC that the company is setting aside a 25 billion yen ($163 million) provision for supply risks, in part to “absorb” the impact from the Nexperia crisis on production.

    Mercedes-Benz is “scurrying around the world to look for alternatives,” CEO Ola Kallenius said. The European Automobile Manufacturers’ Association said members including BMW, Renault, Volkswagen and Volvo have been forced to use their reserve stockpiles of chips and warned of assembly line stoppages if they run out.

    The European Union’s trade commissioner, Maros Sefcovic, on Saturday noted “encouraging progress,” writing on X that China’s Commerce Ministry had confirmed “further simplification” of export procedures for Nexperia chips to the EU and global customers.

    In Beijing, the Commerce Ministry also said Saturday that it agreed to a Dutch request to send representatives to China for “consultations.”

    But it noted that the Netherlands had not taken any concrete actions yet to restore the global semiconductor supply chain since the Dutch government said days earlier it would take “appropriate steps on our part where necessary.”

    Economics Affairs Minister Vincent Karremans had said in that statement that “the Netherlands trusts that the supply of chips from China to Europe and the rest of the world will reach Nexperia’s customers over the coming days.”

    Honda has received word that Nexperia’s shipments from China have resumed, Executive Vice President Noriya Kaihara told reporters Friday. He said the Japanese automaker expects to resume production during the week of Nov. 21 at its plant in Celaya, Mexico, which can make up to 200,000 vehicles a year.

    ___

    AP Business Writer Yuri Kageyama in Tokyo contributed to this report.

    Continue Reading